论文部分内容阅读
本文报告英国胸科结核病协会对696例(15～70岁)肺结核用利福平(R)加异菸肼(H)和头2个月再加乙胺丁醇(E)或链霉素(S)三药治疗6、9、12或18个月(EHR_6、EHR_9、EHR_(12)或EHR_(18),或SHR_6、SHR_9、SHR_(12)或SHR_(18))的研究结果。患者分两组:A组治疗前胸片上无空洞或空洞直径<2厘米;B组空洞直径>2厘米。A组随机用EHR_6或EHR_(12),或SHR_6或SHR_(12)方案;B组随机用EHR_9或EHR_(18),或SHR_9或SHR_(18)方案。两组中凡年龄在60岁以上者均只用EHR方案。利福平、异菸肼和乙胺丁醇分别为600毫克(50公斤以下者450毫克)、300毫克/天和25毫克/公斤/日空腹1次口服。链霉素为0.75克/日肌注,每周用6日。患者治疗前做痰培养和药敏试验2次;化疗时每月查痰
This article reports that the British Thoracic Society for Tuberculosis reported on 696 pulmonary tuberculosis patients (15 to 70 years of age) with isoniazid (R) plus isoniazid (H) and first 2 months plus ethambutol (E) or streptomycin S) drug treatment for 6, 9, 12 or 18 months (EHR_6, EHR_9, EHR_ (12) or EHR_ (18), or SHR_6, SHR_9, SHR_ (12) or SHR_ (18)). Patients were divided into two groups: A group before treatment no chest or empty hole diameter <2 cm; B group hole diameter> 2 cm. Patients in group A were randomized to receive EHR_6 or EHR_ (12) or SHR_6 or SHR_ (12); and those in group B were randomized to receive EHR_9 or EHR_ (18) or SHR_9 or SHR_ (18). EHR regimen was used only for those aged over 60 in both groups. Rifampicin, isoniazid and ethambutol were orally administered orally at 600 mg (450 mg for sub-50 kg), 300 mg / day and 25 mg / kg / day, respectively. Streptomycin 0.75 g / day intramuscular injection, with 6 days a week. Patients before treatment to do sputum culture and drug sensitivity test 2; sputum sputum every month when chemotherapy